DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitisECCO’23 Copenhagen 2023
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signatureECCO’23 Copenhagen 2023
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO’23 Copenhagen 2023
DOP38: Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction TherapyECCO’23 Copenhagen 2023
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension studyECCO’23 Copenhagen 2023
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinibECCO’23 Copenhagen 2023
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trialECCO’23 Copenhagen 2023
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 Copenhagen 2023
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patientsECCO’23 Copenhagen 2023
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot studyECCO’23 Copenhagen 2023
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTEECCO’23 Copenhagen 2023
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel DiseaseECCO’23 Copenhagen 2023
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitisECCO’23 Copenhagen 2023
DOP48: Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn’s disease. The ENIGMA study.ECCO’23 Copenhagen 2023
DOP49: Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn’s disease. The ENIGMA study.ECCO’23 Copenhagen 2023
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiotaECCO’23 Copenhagen 2023
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn’s disease patientsECCO’23 Copenhagen 2023